NCT05178693View on ClinicalTrials.gov

Lutathera and ASTX727 in Neuroendocrine Tumours

PHASE1RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

April 25, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Neuroendocrine Tumors
Interventions
DRUG

ASTX727

Cedazuridine 100mg + 35mg decitabine

RADIATION

Lutathera

Peptide receptor radionuclide therapy (PRRT)

Trial Locations (1)

W12 0HS

RECRUITING

Hammersmith Hospital, London

Sponsors
All Listed Sponsors
collaborator

Advanced Accelerator Applications

INDUSTRY

lead

Imperial College London

OTHER